Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Stéphane Bancel

Stéphane Bancel

CEO of Moderna Therapeutics

Appears in 4 stories

Born: 1972 (age 53 years), Marseille, France
Net worth: 1.8 billion USD (2026)
Education: Ecole Centrale Paris (1992–1995), University of Minnesota (1994–1995), Harvard University, and more
Nationality: French

Notable Quotes

"The publication of these peer-reviewed positive results in the New England Journal of Medicine reflects the strength of the clinical evidence supporting our ongoing regulatory submissions."

"Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future. In 2026, we will return to revenue growth and end the year with a strong balance sheet, with more than $5 billion in liquidity, as we drive toward breakeven in 2028." — Statement on March 3, 2026

"We used to call it personalized cancer vaccine. But what we do is one step further—we design a medicine just for you." — ASCO 2024

Stories

Moderna's mRNA flu vaccine clears Phase 3 with superior efficacy

New Capabilities

Pushing mRNA-1010 through a hostile US regulatory environment

For 80 years, flu vaccines grew in chicken eggs — a process effective against roughly 40% of infections in good years. On May 8, the New England Journal of Medicine published Moderna's Phase 3 data: mRNA-1010 reduced influenza illness by 26.6% more than a standard shot in 40,805 adults aged 50 and older. Moderna's stock rose 16% that day.

Updated 5 days ago

Moderna's battle over the delivery technology in its COVID vaccine

Rule Changes

Led settlement decision

For four years, the question of whether Moderna owed billions for technology at the heart of its COVID-19 vaccine hung over the company. Less than a week before a jury trial was set to begin in Delaware, Moderna agreed to pay up to $2.25 billion to settle patent claims brought by Arbutus Biopharma and Genevant Sciences—accepting a court judgment that it infringed four patents and that those patents are valid. If the full amount is paid, it would be the largest disclosed patent settlement in pharmaceutical history, surpassing a $2.15 billion Pfizer-Takeda settlement in 2013.

Updated Mar 4

Therapeutic cancer vaccines emerge from decades of development

New Capabilities

Leading Moderna's oncology pipeline

Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely—all remain alive today. Researchers discovered these survivors still carry specialized immune cells capable of recognizing their cancer, pointing to a mechanism that could make therapeutic cancer vaccines work reliably.

Updated Jan 31

The first personalized cancer vaccine reaches pivotal testing

New Capabilities

Positioning Moderna's cancer vaccine pipeline as core to post-pandemic strategy

Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit—until now. On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine, combined with the immunotherapy Keytruda, cut the risk of melanoma recurrence or death by 49% at five years in a Phase 2b trial of 157 patients. The sustained result—identical to the three-year mark—suggests the vaccine permanently reprograms immune surveillance rather than offering temporary protection.

Updated Jan 25